Next to advanced non-small cell lung cancer, TG4010 could work on several other cancer types like prostate and breast cancer, possibly making it a rival to Roche's Avastin.
Thursday, June 4, 2009
Transgene sees cancer deal this summer
Transgene expects to strike a worldwide partnership agreement this summer for lung cancer vaccine TG4010, a possible blockbuster, that could speed up the French biotech's plans to become a pharmaceutical group.
Next to advanced non-small cell lung cancer, TG4010 could work on several other cancer types like prostate and breast cancer, possibly making it a rival to Roche's Avastin.
Next to advanced non-small cell lung cancer, TG4010 could work on several other cancer types like prostate and breast cancer, possibly making it a rival to Roche's Avastin.
Subscribe to:
Post Comments (Atom)
Kick Butts Today!
No comments:
Post a Comment